Care continues
Read past the headline
Ask what a source can tell you and what it leaves unanswered.
Rules and advertised prices recorded on September 26, 2026. Both may change.
Approval is about the product
A review by FDA, the Food and Drug Administration, concerns a specific medicine product. Compounded means made to order. Such a product has no FDA review before marketing.
A government drug directory identifies a product with its National Drug Code, shortened to NDC. That code cannot serve as evidence of approval, FDA says.
Ask whether the record describes the exact medicine being offered. The ingredient’s name identifies what the medicine contains. A government drug-directory entry gives a product code. Neither tells you that the finished medicine is FDA-approved.
Guidance and law do different jobs
For state medical boards, the Federation of State Medical Boards serves as a national source of advice on how care should work. Each state sets the rules that clinicians must follow for online care.
FDA warning letters describe concerns at a point in time. Later discussions or responses may change the issues; a letter is not a final court finding.
When reading a headline about a rule, look for its date and whether it describes guidance, a proposal, or an action already in force.
Reports and offers have limits
FDA says a reported medicine problem does not establish its cause. Such reports cannot measure how often the problem happens.
Advertised cash prices are offers, not records of what people paid. Starter terms and refill timing can change the amount.
Ask which claim the source actually supports. Keep a fact about a medicine separate from a promise that it will help you.
Take these questions to the visitSource notes for this page
If a business has no FDA warning letter, that does not mean FDA approves what it does. FDA may simply not have reviewed it.